Oral Immunostimulant Could Improve Effectiveness of COVID-19 Vaccines by Increasing IgG Binding Antibody Responses
By HospiMedica International staff writers Posted on 09 Jul 2020 |
Illustration
Preclinical studies of an oral integrin activator that promotes cell adhesion have demonstrated that it significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2) and can be used as an immunostimulant for any COVID-19 vaccine.
The oral integrin activator, 7HP349 developed by 7 Hills Pharma (Houston, TX, USA) has the potential not only to augment the vaccines’ effectiveness, but also accelerate immune system response, allow for dose sparing and reduce or eliminate the need for boosters.
7HP349 is 7 Hills Pharma’s lead product candidate in a platform of patent-protected small molecule integrin activators that significantly enhance cell adhesion, which is essential for producing an immune response. The company is working to develop 7HP349 as an oral immunostimulant for COVID-19 and seasonal influenza vaccinations. In preclinical studies, the product has shown effectiveness in augmenting influenza, tuberculosis, and Chagas vaccines, and has demonstrated a positive safety profile.
“We expect our cell adhesion agents will greatly enhance the efficacy of emerging vaccines against this coronavirus,” said 7 Hills Pharma President and CEO Upendra Marathi, Ph.D., MBA. “Although this approach is potentially applicable for all ages, we are targeting older subjects who are at greater risk because of their lower immune responses to vaccines.”
Related Links:
7 Hills Pharma
The oral integrin activator, 7HP349 developed by 7 Hills Pharma (Houston, TX, USA) has the potential not only to augment the vaccines’ effectiveness, but also accelerate immune system response, allow for dose sparing and reduce or eliminate the need for boosters.
7HP349 is 7 Hills Pharma’s lead product candidate in a platform of patent-protected small molecule integrin activators that significantly enhance cell adhesion, which is essential for producing an immune response. The company is working to develop 7HP349 as an oral immunostimulant for COVID-19 and seasonal influenza vaccinations. In preclinical studies, the product has shown effectiveness in augmenting influenza, tuberculosis, and Chagas vaccines, and has demonstrated a positive safety profile.
“We expect our cell adhesion agents will greatly enhance the efficacy of emerging vaccines against this coronavirus,” said 7 Hills Pharma President and CEO Upendra Marathi, Ph.D., MBA. “Although this approach is potentially applicable for all ages, we are targeting older subjects who are at greater risk because of their lower immune responses to vaccines.”
Related Links:
7 Hills Pharma
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans